Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4 Purity >98.0% (HPLC) Lenvatinib Mesylate Intermediate Factory

Short Description:

Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate

CAS: 205448-66-4

Purity: >98.0% (HPLC)

Appearance: Off-White to Yellow Solid Powder

Intermediate of Lenvatinib Mesylate CAS 857890-39-2

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Ruifu Chemical Supply Lenvatinib Mesylate Intermediates With High Purity
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib; 1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4

Chemical Properties:

Chemical Name	Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate
Synonyms	Lenvatinib Impurity 47; 4-Chloro-7-Methoxyquinoline-6-Carboxylic Acid Methyl Ester; 4-Chloro-7-Methoxy-6-Quinolinecarboxylic Acid Methyl Ester; Lenvaint-D
CAS Number	205448-66-4
CAT Number	RF-PI1970
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C12H10ClNO3
Molecular Weight	251.67
Boiling Point	377.4±37.0℃
Density	1.320±0.06 g/cm3
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	Off-White to Yellow Solid Powder
1 H NMR Spectrum	Consistent With Structure
Purity / Analysis Method	>98.0% (HPLC)
Loss on Drying	<1.00%
Total Impurities	<2.00%
Test Standard	Enterprise Standard
Usage	Intermediate/Impurity of Lenvatinib Mesylate (CAS: 857890-39-2)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

FAQ:

Application:

Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate (CAS: 205448-66-4) is an intermediate of Lenvatinib Mesylate (CAS: 857890-39-2). Lenvatinib is a thyroid cancer drug developed by Eisai Corporation of Japan (Code: E7080), belonging to the inhibitor of oral multi-receptor tyrosine kinase (RTK) and can inhibit the kinase activity of the vascular endothelial growth factor Receptors R1 (FLT1), VEG-FR2 (KDR), R3 (FLT4). Lenvatinib can also inhibit the involvement of other RTKs in pathological angiogenesis, tumor growth, and cancer progression except for their normal cellular functions including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; platelet-derived growth factor receptor (PDGFR [alpha]), KIT, and RET. [Indications]: Lenvatinib is suitable for the treatment of patients of thyroid cancer of local recurrence or metastasis type, progressivity type and radioactive iodine-refractory differentiated type.